Peijia Medical Limited announced that partial clinical data of two feasibility studies of the HighLife SAS Transcatheter Mitral Valve Replacement system, the company's licensed-in TMVR product that uses a transeptal approach to treat patients with mitral regurgitation, has been presented at the third Chinese Structural Heart Diseases Congress held between April 15­17, 2021. Technical success, safety events and hemodynamic performance of the first 18 consecutive patients treated in the feasibility studies were reported in the presentation. For these 18 patients, 16 patients had a successful valve implantation and were followed up. There was no conversion to surgery or re-intervention in any of these 18 patients. Of the 16 implanted patients, one passed away during the follow-up period. The remaining 15 patients are alive to date, and have no major stroke, myocardial infarction, left ventricular outflow tract obstruction, device migration, embolization or fracture, and no conversion to surgery. Hemodynamic performance of these 15 patients improved from 3+/4+ mitral regurgitation to non/trace/1+ grade. Shareholders of the Company and potential investors can refer to the presentation by Dr. Ruediger Lange at the third Chinese Structural Heart Diseases Congress for further details of the product and the clinical studies.